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Available online 29 May 2012Abstract In vitro generation of large numbers of autologous hematopoietic stem cells would be extremely useful for clinical
applications. Adipose tissue derived mesenchymal stem cells (AT-MSC) are an easily available autologous source for cell therapy
applications. Like hematopoietic cells, MSC are of mesodermal origin. The Cdx–Hox pathway is an important genetic program for
hematopoiesis, where Cdx4 is a key upstream regulator of the Hox family. We introduced ectopic CDX4 gene in an attempt to
reprogram AT-MSC to differentiate along the hematopoietic lineage. To further promote hematopoietic reprogramming, we
cultured the transduced cells in cocktails of hematopoietic cytokines, growth factors or epigenetic modifiers. However, despite
strong expression of CDX4 at the mRNA and protein levels, neither downstream HOX genes, other genes of importance for
hematopoietic development or functional colony forming assays showed any evidence of hematopoietic reprogramming. Thus,
despite the close developmental association between these cell types, the introduction of one single master switch transcription
factor was not sufficient to promote hematopoietic reprogramming in AT-MSC.
© 2012 Elsevier B.V. All rights reserved.IntroductionHematopoietic stem cells (HSC) have been used in clinical
transplantation for decades. Transplantation of autologousAbbreviations: CDX4, caudal type homeobox 4; HOX, homeobox;
HSC, hematopoietic stem cells; HLA, human leukocyte antigen;
BMP4, bone morphogenetic protein 4; IL3, interleukin-3; SCF, stem
cell factor; Flt-3 ligand, Fms-related tyrosine kinase-3 ligand; TPO,
thrombopoietin; 5-AzaC, 5-azacytidine; TSA, trichostatin A.
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doi:10.1016/j.scr.2012.05.006marrow is used to treat patients with different neoplastic
diseases (Armitage and Gale, 1989; Copelan, 2006). Prior to
bone marrow transplantation the patient will receive high
dose chemotherapy, and attempts are made to deplete the
marrow of malignant cells, but the remaining cancer cells still
lead to relapse in many patients. Allogeneic transplantation
using bone marrow from human leukocyte antigen (HLA)
identical family donors gives the best clinical outcome in
patients with several hematopoietic malignancies (Armitage,
1992; Devetten and Armitage, 2007). Unfortunately such
donors are often not available, and the patient has to undergo
transplantation with HLA discordant bone marrow from a
136 K. Szöke et al.family donor, or marrow obtained from a donor identified
through a marrow donor registry. Transplantation of these
bone marrows is more likely to cause life-threatening graft-
versus-host disease. In both these settings, if HSC could be
made from the patient's own cells, presumably they would be
the HSC best suited to restore the blood and immune system
with no risk of cancer cell contamination or alloimmune side
effects.
Adipose tissue derived mesenchymal stem cells (AT-MSC)
are an easily available autologous source of multipotent cells
for cell therapy applications (Pittenger et al., 1999; Zuk et al.,
2002). Like HSC, MSC derive from embryonic mesoderm. When
cultured in hematopoietic differentiation medium, AT-MSC
could be shown to adopt gene expression and functionality
similar to macrophages of the hematopoietic lineage
(Freisinger et al., 2010). In 2006, Yamanaka and his colleagues
showed how transduction of a set of defined genes could
reprogram fibroblasts to become pluripotent cells (Takahashi
and Yamanaka, 2006; Takahashi et al., 2007; Park et al., 2008).
Recently, reprogramming to pluripotency has been achieved by
single gene transduction of OCT4 (Kim et al., 2009). In another
study, OCT4 transduction of human fibroblasts was shown to
generate hematopoietic progenitor cells (Szabo et al., 2010).
Based on these studies, and starting with MSC that have a
certain similarity to HSC, we hoped to be able to generate HSC
by transduction of a single gene, and at the same time avoid
the potential dangers of pluripotency that may follow OCT4
transduction.
Studies in zebrafish have identified the caudal-related
homeobox containing transcription factors (cdx) and poste-
rior hox genes as key regulators for blood formation during
embryonic development. By the activation of downstream
hox targets, cdx genes pattern hematopoiesis in zebrafish
(Davidson et al., 2003; Davidson and Zon, 2006) and can
promote hematopoiesis from mouse embryonic stem cells
(mESC) (Wang et al., 2005b; Lengerke et al., 2007, 2008).
The ectopic expression of Cdx4 and HoxB4 genes enables the
derivation of mESC‐derived HSC (Wang et al., 2005b).
Furthermore, bone morphogenetic protein 4 (BMP4), Wnt3a
and hematopoietic cytokines direct blood formation via
activation of Cdx and Hox genes in mESC and in human
induced pluripotent stem cells (iPS) (Lengerke et al., 2008,
2009) suggesting the conservation of blood patterning
pathways between mouse and human hematopoietic devel-
opment. Therefore, we assumed that the CDX–HOX pathway
might play a similarly central role in human hematopoietic
development, with CDX4 acting as a master switch gene on
downstream HOX genes, which in turn would induce the
genetic program required for hematopoiesis.
CDX4 is not expressed in AT-MSC. In order to directly
reprogram AT-MSC to HSC, we used a retroviral transduction
system to induce stable human CDX4 expression in these cells.
Additionally, we exposed the cells to the hematopoietic
cytokines interleukin-3 (IL3), stem cell factor (SCF), Fms-
related tyrosine kinase-3 (Flt-3) ligand and thrombopoietin
(TPO), or to BMP4, or to the epigeneticmodifiers 5-azacytidine
(5-AzaC) and trichostatin A (TSA). However, despite high
expression of CDX4 at the mRNA and protein levels, real-time
PCR results showed no effect on downstream HOX genes or
other genes of importance for hematopoietic development,
and functional colony forming assays showed no hematopoietic
colonies. These results indicate that the introduction ofa single master switch gene and exposure of the AT-MSC
to epigenetic modifiers or hematopoietic cytokines is not
sufficient to induce cell fate changes in MSC, at least under
these conditions.
Materials and methods
All reagents were purchased from Sigma Aldrich, St. Louis,
MO unless otherwise stated.
Isolation of MSC from human adipose tissue
ATwas obtained by liposuction from abdominal, hip, and thigh
regions of healthy donors (age 18–39) with informed consent,
and the collection and storage of AT and AT-MSC were
approved by the regional committee for ethics in medical
research. The stromal vascular fraction (SVF) was separated
from AT as described previously (Boquest et al., 2005). Briefly,
lipoaspirate (300–1000 ml) was washed repeatedly to remove
erythrocytes and leukocytes with Hanks' balanced salt solution
(HBSS; Gibco, Invitrogen, Paisley, UK) containing antibi-
otics (100 IU/ml penicillin and 100 IU/ml streptomycin) and
2.5 μg/ml amphotericin B and digested for 75 min applying
constant gentle rotation at 37 °C using 0.1% collagenase A
type 1. The digest medium containing floating adipocytes and
free oil were separated from the SVF by centrifugation at
400 ×g for 10 min at room temperature. The remaining SVF
cells were re-suspended in HBSS containing antibiotics and 2%
fetal bovine serum (FBS, BioWhittaker, Lonza, Verviers,
Belgium). Suspended cells were filtered through 100 μm and
then 40 μm cell sieves (Becton Dickinson, San Jose, CA). SVF
cells were obtained from the interface after Lymphoprep
gradient separation (Axis Shield, Oslo, Norway) at 400 ×g for
30 min, washed and re-suspended in HBSS containing antibi-
otics and 2% FBS. Cell counts and viability assessment were
performed using acridine orange/ethidium bromide staining
and analyzed by a fluorescence microscope.
AT-MSC were isolated from the SVF using magnetic cell
sorting. Endothelial cells (CD31+) and leukocytes (CD45+)
were removed using magnetic beads directly coupled to
mouse anti-human CD31 and CD45 monoclonal antibodies
(MAb) (Miltenyi Biotech, Bergish Gladbach, Germany) and LS
columns according to the manufacturer's protocol. Flow
cytometry analyses showed that no more than 5% of CD31+
and CD45+ cells were left in the suspension (data not shown).
Cells were washed and re-suspended in Dulbecco’s modified
Eagle’s medium (DMEM/F12) (Gibco, Invitrogen, Paisley, UK)
containing 20% FBS and antibiotics.
Culturing of AT-MSC
Cells were washed and re-suspended in DMEM/F12 containing
20% FBS, antibiotics and amphotericin B. Cultures were
maintained at 37 °C in an atmosphere of 5% CO2 in humid
air. After 4–7 days unbound cells were removed and the
medium was replaced. At 50% confluence, cell adherence was
interrupted with trypsin–EDTA solution, and the cells were
inoculated into new flasks at 5000 cells/cm2. After the first
passage 10% FBS was used and amphotericin B was withdrawn
from the culture. The medium was replaced every 2–3 days.
Table 1 List of primers used in real-time RT-PCR.
Gene title Gene
symbol
TaqMan assay number
(Applied Biosystems)
Caudal type homeobox 4 CDX4 Hs00193194_m1
Fetal liver kinase-1 FLK1 Hs00176676_m1
GATA binding protein 2 GATA2 Hs00231119_m1
Runt-related transcription
factor 1
RUNX1 Hs00231079_m1
Stem cell leukemia/T-cell
acute lymphocytic
leukemia 1
SCL/
TAL-1
Hs00268434_m1
Homeobox A6 HOXA6 Hs00430615_m1
Homeobox A7 HOXA7 Hs00600844_m1
Homeobox A9 HOXA9 Hs00365956_m1
Homeobox A10 HOXA10 Hs00172012_m1
Homeobox B4 HOXB4 Hs00256884_m1
Homeobox B7 HOXB7 Hs00270131_m1
Homeobox B9 HOXB9 Hs00256886_m1
Glyceraldehyde
3-phosphate
dehydrogenase
GAPDH Hs99999905_m1
Cyclin-dependent kinase
inhibitor 1A
CDKN1A Hs00355782_m1
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were counted at each passage.
Retroviral transduction of AT-MSC
MSCV-CDX4-IRES-GFP vector was kindly provided by George
Q. Daley, Harvard Medical School Boston, MA. Retroviral
supernatants were produced in Phoenix cells. Cells were
grown in DMEM containing antibiotics and 10% FBS and
passaged at 1:4 every 2–3 days at 70–80% confluence.
Lipofectamine 2000 transfection reagent (Invitrogen Corpo-
ration, Carlsbad, CA) was used for the transfection of viral
plasmid MSCV-CDX4-IRES-GFP to the packaging Phoenix cell
line according to the manufacturer's specifications. The
medium was replaced the day after transfection. Retroviral
supernatants were collected 2–3 days after transfection.
RetroNectin (Takara Bio Inc., Shiga, Japan) was coated into
non-tissue culture treated plates (BD Falcon, BD Biosciences,
Franklin Lakes, NJ) at the concentration of 25 μg/ml to
cover a plate at 5 μg/cm2. Plates were incubated overnight
at 4 °C. Then RetroNectin was removed and plates were
blocked with 2% BSA (New England Biolabs, Ipswish, MA) for
30 min at room temperature. Plates were washed with
phosphate-buffered saline (PBS). Then retroviral superna-
tant was added, and the plates were centrifuged at 1500 ×g
for 2 h at 32 °C. After centrifugation the viral supernatant
was discarded, and the plates were washed with PBS. Target
cells were added to the plates in growth medium and
centrifuged at 600 ×g for 5 min to promote contact between
target cells and viral vector. After the spin-infection cells
were incubated overnight at 37 °C. Expression of GFP as a
sign of successful transduction was analyzed after 2–3 days
using a fluorescence microscope. Cells were sorted based on
GFP expression using a FACS Vantage cell sorter (Becton
Dickinson, San Jose, CA). The purity of sorted cells was
verified by flow cytometry one week after sorting.
Cell culture modifications
Non-transduced and CDX4-transduced AT-MSC, in log phase of
growth, were seeded in 25-cm2 tissue culture flasks at
4000 cells/cm2 (Nunc, Roskilde, Denmark) for one week. In
one series of experiments, the hematopoietic cytokines IL3,
SCF, Flt-3 ligand and TPO (20 ng/ml; PeproTech EC, London,
UK) were used in a differentiation cocktail to promote
hematopoietic differentiation. In another series of experi-
ments BMP4 (20 ng/ml) was added to the cultures. Finally, to
facilitate epigenetic changes, the cells were incubated in
medium containing 5-AzaC at 1 μmol/l for 24 h, then washed
three times with medium and cultured in medium containing
10 ng/ml TSA. In another set of the experiments a combination
of those factors was used. The medium containing fresh
cytokines, TSA and BMP4 was replaced every second day until
the experiment was terminated, at day 7.
Hematopoietic colony forming assay
To determine the effect of ectopic CDX4 overexpression in
AT-MSC on hematopoietic colony formation, colony forming
unit assays were performed using methylcellulose medium
(MethoCult; StemCell Technologies Inc., Vancouver, BC,Canada) supplemented with hematopoietic cytokines, IL3,
IL6, Epo and SCF. 3.6 ml MethoCult were mixed with 400 μl
cell suspension at the density of 20,000 cells per dish. Colony
forming assays were performed in 3 parallel culture dishes for
colony growth (StemCell Technologies Inc.). Plates were
incubated at 37 °C in an atmosphere of 5% CO2 in humid air
for 14 days and then inspected under the microscope for
colony formation.
Real-time RT-PCR analysis
Total RNA was extracted from cells using RNAqueous‐Micro Kit
(Applied Biosystems/Ambion, Austin, TX) according to the
manufacturer’s protocol and treated with DNase I (Applied
Biosystems/Ambion). Reverse transcription (RT) was per-
formed using High-Capacity cDNA Reverse Transcription Kit
(Applied Biosystems) following the manufacturer’s protocol
with 200 ng total RNA per 20 μl RT reaction. Relative
quantification was performed using the 7300 Real-time RT-
PCR system (Applied Biosystems) and TaqMan Gene Expression
Assay (Applied Biosystems) reagents according to the manu-
facturer’s description. The thermocycler parameters were
95 °C for 10 min followed by 40 cycles of 95 °C for 15 s and
60 °C for 1 min. All primers are provided in Table 1. All
samples were run in triplicates. After verifying the stable
expression of glyceraldehyde 3-phosphate dehydrogenase
(GAPDH), this gene was selected as endogenous control.
CDKN1A was used as endogenous control in experiments
involving the empty vector-transduced cells. Relative mRNA
levels were calculated by the comparative CT method, where
the threshold cycle (CT) values are given by the 2−ΔΔCt formula
(Livak and Schmittgen, 2001). Differential expression of all
markers was calculated in relation to the corresponding non-
transduced untreated cells.
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CDX4 transduced AT-MSC were grown on gelatin-coated
chamber slides (BD Falcon, 4.0 cm2 per chamber). After
reaching confluence, cells were fixed with 4% paraformalde-
hyde (PFA). Cells were thenwashed with three changes of PBS.
Fixed cultures were permeabilized in 0.25% Triton X for 10 min
and then blocked in 10% FBS for 1 h, followed by incubation
with mouse anti-human CDX4 (1:100; R&D Systems,
Minneapolis, MN) primary antibody in a humidified chamber
at 4 °C overnight, then washed three times in PBS. Cells were
visualized using Texas Red-conjugated anti-mouse IgG second-
ary antibody (1:500; Jackson ImmunoResearch Laboratories
Inc., West Grove, PA) at room temperature for 1 h. Unbound
antibody was removed with three washes in PBS then analyzed
for the expression of CDX4. The slides were mounted with
Vectashield mounting medium for fluorescence containing
4′,6-diamidino-2-phenylindole (DAPI) (Vector Laboratories
Inc., Burlingame, CA) for nuclear visualization. As a control,
secondary antibody alone was used to assess nonspecific
fluorescence.GFP 
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Figure 1 Phase contrast morphology and flow cytometry of
green fluorescent protein (GFP) expression of AT-MSC following
CDX4 transduction. (A) Light microscopy of a confluent monolayer
of CDX4 transduced AT-MSC exhibiting typical spindle-like
morphology. Cultures were examined by a Leica DMIL inverted
microscope. Image was taken with a Leica DFC 320 camera
(Leica Microsystems, Wetzlar, Germany) using Adobe Photoshop
7.0 software and a 10×/0.22 Leica objective lens. Scale bar
represents 50 μm. (B) Flow cytometry histogram of cells from
donor 1, representative of the three donors after CDX4 transduc-Western blot analysis
Lenti-X, HEK 293T transiently transfected cells (Clontech,
Takara Bio, Saint-Germain-en-Laye, France) were lysed by
boiling in 2× Laemmli sample buffer. The lysate (10 μl;
equivalent to 100,000 cells) was separated on 12% SDS-
polyacrylamide gel and transferred to a polyvinylidene
fluoride (PVDF) membrane. The blot was probed with goat
anti-human CDX4 polyclonal antibody (0.3 μg/ml; R&D Sys-
tems), followed by a biotin labeled secondary anti-goat
antibody. The membrane was incubated with streptavidin/
horseradish peroxidase (HRP) and the HRP signal was detected
by chemiluminescent. The membrane was then washed and
re-probed with Living Colors GFP monoclonal antibody
(1:1000; Clontech), followed by a biotin labeled secondary
anti-mouse antibody. GFP expression was again detected
based by HRP activity.tion and cell sorting. Gray histogram represents cells expressing
GFP. Negative control is overlaid in a black line on the histogram.Results
Stable expression of human CDX4 in AT-MSC
following retroviral transduction
AT-MSC were infected with retrovirus and FACS sorted based
on the green fluorescent protein (GFP) expression of the
transduced cells. CDX4 overexpressing cells maintained AT-
MSC morphology up to five weeks after cell sorting (Fig. 1A).
To control the transgene expression in the transduced cells,
flow cytometry analysis was performed. The GFP expression
was analyzed in the transduced cells one week after sorting
(Fig. 1B). To verify the CDX4 protein expression in the
transduced cells, immunocytochemistry was performed two
months after retroviral infection. Comparison of the CDX4
protein expression in Fig. 2A with the GFP in Fig. 2B shows
that most of the cells still express these proteins, and that
the intensity of expression is highly correlated. As further
documentation that CDX4 is actually expressed in transfected
cells, we performed transient transfection of HEK293T cellsusing the same CDX4 vector. Supplementary Fig. 2 shows CDX4
and GFP protein expression in these cells by Western blot
analysis.Downstream effect of CDX4 transduction and
exposure to hematopoietic cytokine cocktail, BMP4
or epigenetic modifiers
Hematopoietic gene expression in CDX4 transduced and
non-transduced AT-MSC
While non-transduced AT-MSC did not express CDX4, CDX4
mRNA expression after transduction was high (Fig. 3A). To
determine the effect of CDX4 on downstream genes of
importance for hematopoietic development, we performed
real-time RT-PCR analysis to determine mRNA expression of
SCL/TAL-1, FLK1, GATA2 and RUNX1, all genes known to be
central for hematopoietic differentiation (Robertson et al.,
139Ectopic expression of CDX4 in human mesenchymal stem cells does not affect HOX gene expression2000; North et al., 2002; Lugus et al., 2007, 2009). In
addition, we determined the mRNA expression of a number
of HOX genes known to be downstream targets of changes in
CDX4 expression (Lohnes, 2003; Davidson and Zon, 2006).
These assays were performed on cells in standard cul-
ture medium, on cells grown with a supplement of theA
B
C
Dhematopoietic cytokines IL3, SCF, Flt-3 ligand and TPO, with
a supplement of BMP4 or supplemented with the epigenetic
modifiers 5-AzaC and TSA. The results of all these experi-
ments, performed on AT-MSC from three different donors,
are shown in Fig. 3A. Fig. 3B presents gene expression data
performed on AT-MSC cultured using either hematopoietic
cytokines or BMP4 as supplement in combination with
epigenetic modifiers.
Supplementary Fig. 1 shows gene expression data using the
empty vector-transduced cells as a means to exclude possible
off-target effects caused by the transduction procedure.
Relative to the expression in non-transduced, non-treated
AT-MSC, the mRNA levels for HOX genes showed some
between-donor variation, but were uniformly unchanged
compared to the non-transduced cells. The same tendency
was observed regarding the expression level of other
hematopoietic-specific genes, like RUNX1, FLK1 and GATA2.
SCL/TAL-1, the most reliable marker for tracking early hema-
topoietic commitment (Zhang et al., 2005) was expressed
neither before nor after CDX4 transduction in our cells (data
not shown). Hematopoietic genes were not upregulated
neither by the addition of hematopoietic cytokines, BMP4 or
epigenetic modifiers nor by the combination of these factors.Hematopoietic colony formation assay
We examined whether CDX4 expression with or without
hematopoietic cytokines, BMP4 or additional epigenetic
modifiers led to the formation of hematopoietic colonies. No
colonies of any kind were detected in any of these dishes,
whether the cells were transduced or not, or treated with
cytokines, BMP4 or epigenetic modifiers or not (data not
shown). All these results show that, despite stable high
expression of CDX4 in the AT-MSC, this had no impact on
genes involved in hematopoietic specification or on assays
indicative of hematopoietic functionality.Discussion
MSC have the potential to differentiate into cells and organs
of mesodermal origin, such as bone, cartilage, fat, tendons
and skeletal muscle (Pittenger et al., 1999; Barry and
Murphy, 2004). There is also increasing evidence for their
ability to transdifferentiate into cells of other lineages
(Schaffler and Buchler, 2007). For this reason we assumed
that it might be possible to reprogram MSC to become HSC,
which are also derived from mesoderm.Figure 2 Immunocytochemistry of CDX4 expression. (A) Immu-
nocytochemistry staining of human CDX4 in red (Texas red)
showing the expression of the protein and (B) GFP co-expression
shown in green. (C) Relevant light microscopy image and
(D) negative control staining using secondary antibody alone to
assess nonspecific fluorescence (scale bars: 50 μm). DAPI stains
the nuclei in blue in each image. Slides were assessed using
a Nikon, Eclipse E600 (Nikon, Kanagawa, Japan) fluorescent
microscope equipped with a Nikon 20×/0.45 objective lens and a
Leica DC 300F digital camera (Leica Microsystems DI, Cambridge,
UK). Images were taken using Adobe Photoshop 7.0 software
(Adobe Systems Norge AS, Oslo, Norway).
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141Ectopic expression of CDX4 in human mesenchymal stem cells does not affect HOX gene expressionPrimitive haematopoiesis is initiated in the yolk sac blood
islands derived from the posterior mesoderm by the
formation of embryonic erythroid cells and endothelial
cells (Palis et al., 1995; Palis and Yoder, 2001; Ferkowicz
and Yoder, 2005). In zebrafish, cdx4 mutants fail to specify
blood progenitors, while cdx4 overexpression during devel-
opment induces blood formation (Davidson et al., 2003). In
this study, the blood deficiency induced by the cdx4
mutation could be rescued by the overexpression of several
hox genes. These findings suggested that, in zebrafish, cdx4
regulates hox genes, and that this axis is essential for the
specification of hematopoiesis during embryogenesis. Later,
the Cdx-Hox pathway was found to be involved also in
murine hematopoiesis (Wang et al., 2005b; Lengerke et al.,
2008). Here, the coordinated activity of Bmp4 and Wnt
signaling was found to be important for hematopoietic fate
specification. In mESC the ectopic expression of Cdx4 was
found to promote hematopoietic progenitor formation
(Wang et al., 2005b). Thus, in zebrafish and mice, the
Cdx4/Hox axis seems to be essential for embryonic
hematopoiesis, and ectopic overexpression of members of
this pathway on a background of pluripotency will promote
hematopoietic development. In human cells, the role of
these genes is not so clear. Overexpression of HOXB4 was
found to promote hematopoietic development in human ESC
(Bowles et al., 2006). However, hematopoietic repopulat-
ing cells have also been generated from hESC independent
of ectopic HOXB4 expression where HOXB4, as a single
master switch gene was unable to induce hematopoietic
repopulating capacity from hESC (Wang et al., 2005a). To
the best of our knowledge, no studies have been able to
demonstrate that the CDX4/HOX axis is of the same
importance for the specification of hematopoiesis in the
human system as that which has been clearly shown in
mice and zebrafish.
However, when we started this work, the data from the
zebrafish and mouse studies had just been released, and a
strategy to induce hematopoiesis in a stem cell population
that could be obtained in very large numbers in the
autologous setting seemed feasible, and with potentially
huge implications in certain clinical situations. We show
here that our retroviral transduction and sorting strategy
gave an almost pure population of transduced cells, that
CDX4 mRNA was absent in non-transduced and highly
expressed in transduced cells, and that this translated into
CDX4 protein expression in practically all the cells. However,
based on results in AT-MSC from three donors, this did not
affect the expression of SCL/TAL-1, RUNX1, FLK1 or GATA2,
all genes that are centrally involved in hematopoietic
specification. When the transduced cells were placed in an
environment that strongly promotes hematopoietic differ-
entiation, no evidence of hematopoietic colony formation
was observed. Attempts to add more hematopoietic repro-
gramming stimuli by including a hematopoietic cytokine
cocktail, BMP4 or epigenetic modifiers in the culture
medium also did not produce hematopoietic colonies. MoreFigure 3 Real-time RT-PCR analysis. (A) Graphs represent express
markers (CDX4; FLK-1; GATA-2; RUNX1; HOXA6; HOXA7; HOXA9; HOX
in CDX4 transduced and non-transduced cells in three donors. (B) G
Graphs were created using GraphPad Prism 5 software (GraphPad Sosurprisingly, the strong expression of CDX4 in the AT-MSC did
not affect the expression of the HOX genes HOXA6, HOXA7,
HOXA9, HOXA10, HOXB4, HOXB7 and HOXB9, which have all
been shown to be upregulated following ectopic Cdx4
expression in mice and to be involved in hematopoietic
development (Davidson et al., 2003; Wang et al., 2005b).
This might suggest that ectopic CDX4 expression in fact
does not induce HOX gene expression in human AT-MSC. In
searching the literature, we have not found any publications
which contradict this hypothesis. Murine Cdx4 has been
found to bind to the human HOXA10 promoter and to induce
HOXA10 transcription in a human myeloid cell line (Bei et
al., 2011), but similar findings have not been observed for
human CDX4 for HOXA10 or any of the other HOX genes.
Thus, we believe that the most likely explanation for our
failure to induce hematopoietic reprogramming by ectopic
expression of CDX4 in AT-MSC is that there may be
epigenetic or other tissue-specific inhibitory factors which
can influence the binding of CDX4 to the HOX promoters.
However, all the HOX genes investigated here were actually
expressed in the AT-MSC, albeit at low levels, suggesting an
open chromatin structure and transcription facilitating
epigenetic states within promoter and enhancer elements
associated with these target genes.
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